Skip to main content
Clinical Trials/NCT02029898
NCT02029898
Completed
Phase 1

Adaptation to Neonatal Life After an Anesthetic Protocol Using Remifentanil for General Anesthesia for Caesarean Section in a Context of Prematurity - REAGI Protocol

University Hospital, Rouen1 site in 1 country53 target enrollmentFebruary 2, 2014

Overview

Phase
Phase 1
Intervention
Remifentanil
Conditions
Cesarean Section
Sponsor
University Hospital, Rouen
Enrollment
53
Locations
1
Primary Endpoint
Apgar Score value below 7 after 5 minutes
Status
Completed
Last Updated
3 months ago

Overview

Brief Summary

One of the problems during general anesthesia (GA) for caesarean section is the place of opioid agents. Indeed, the literature does not provide so far a clear answer regarding the use of opioids prior to extraction of the newborn. Indeed, if the opioid administration at induction is beneficial for the mother (better control of autonomic responses to noxious stimuli), the impact on the newborn can be unfavorable in terms of adaptation to extrauterine life . This is especially true if the birth takes place in a context of prematurity and / or acute fetal distress.

The pharmacokinetics of remifentanil make it the only opioid which is consistent with a rapid sequence induction. Its short period of action avoids the manual ventilation of patients before intubation, while providing a peak of action concomitant to the nociceptive stimulation. Patients at high risk of aspiration, including pregnant women, may benefit from this type of morphine at induction. In addition, the fact that remifentanil seems to be associated with relative fetal safety in obstetrical or neonatal context legitimized the development of protocols to study maternal-fetal consequences of the use of remifentanil at induction of AG for emergency caesarean section.

While cesarean section under general anesthesia mainly concern premature newborns in France, no work has focused on the use of remifentanil for caesarean section in a context of preterm without preeclampsia.

The main hypothesis of this study is to evaluate the safety of the use of remifentanil in terms of adaptation to extrauterine life in children born prematurely by caesarean section under general anesthesia outside the context of preeclampsia.

To do this, we will compare two groups of children, one consisting of children born by cesarean section under general anesthesia with maternal remifentanil infusion, the other made up of children born by cesarean section under general anesthesia without maternal infusion of remifentanil. This study is prospective, single-center, randomized, double-blinded.

The primary endpoint is formed by the value of the Apgar score less than 7 at 5 minutes, calculated in the delivery room by the team supporting the child (midwives and pediatricians).

The secondary endpoints are formed by maternal hemodynamic parameters (SBP, DBP, MAP, HR), the rate of complications during induction (difficult intubation, aspiration), the onset of respiratory distress requiring ventilation mask in the newborn, the rate of intubation in neonates, and the rate of use of adjuvant anesthetic agents.

Registry
clinicaltrials.gov
Start Date
February 2, 2014
End Date
June 22, 2018
Last Updated
3 months ago
Study Type
Interventional
Study Design
Parallel
Sex
Female

Investigators

Sponsor
University Hospital, Rouen
Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Inclusion criteria of the mother:
  • Patient over 18 years
  • Single pregnancy with an indication for cesarean section under general anesthesia context of prematurity (\<37SA)
  • Patient informed and written consent for participation in this research signed
  • Affiliation to social security
  • Inclusion criteria of the child:
  • Parents informed and written consent signed by the father and mother for the participation in this research by the child (unless a parent no longer has parental authority)

Exclusion Criteria

  • Non-inclusion criteria of the mother:
  • Vaginal Delivery
  • Mother pathology requiring the use of an opioid during induction
  • Severe Preeclampsia
  • More than 14 weeks between the information and the inclusion
  • Patient under guardianship
  • Non-inclusion criteria of the child:
  • Fetal pathology diagnosed in the prenatal period involving the prognosis of the child

Arms & Interventions

Remifentanil

injectable solution, 0.5 microgramme/Kg for 30 seconds following by a continuous dose of 0.1 microgramme/kg/minute

Intervention: Remifentanil

Placebo

injectable solution 0.9% for the end of surgery

Intervention: sodium chloride 0,9%

Outcomes

Primary Outcomes

Apgar Score value below 7 after 5 minutes

Time Frame: 5 minutes afer birth

Apgar Score value below 7 after 5 minutes calculated in the delivery room by the team supporting the child (midwives or pediatric)

Secondary Outcomes

  • Rate of complications of induction (difficult intubation, inhalation)(intraoperative)
  • Intubation rate among newborns(intraoperative)
  • Occurrence of respiratory distress requiring mask ventilation of the newborn(intraoperative)
  • Rate of the use of adjuvant anesthetic agents(intraoperative)
  • Maternal hemodynamic parameters (SBP, DBP, MAP, HR),(intraoperative)
  • Umbilical cordon blood pH(intraoperative)

Study Sites (1)

Loading locations...

Similar Trials

Active, not recruiting
Phase 1
Adaptation to neonatal life after an anesthetic protocol using remifentanil for general anesthesia for caesarean section in a context of prematurity - REAGI Protocol (Remifentanil for General Anesthesia in the context of Immaturity)pregnant woman older than 18 years with an indication for caesarean section under general anesthesia in a context of prematurity.MedDRA version: 18.0Level: HLGTClassification code 10026908Term: Maternal complications of pregnancySystem Organ Class: 10036585 - Pregnancy, puerperium and perinatal conditionsTherapeutic area: Analytical, Diagnostic and Therapeutic Techniques and Equipment [E] - Anesthesia and Analgesia [E03]
EUCTR2013-001850-83-FRCHU- Hôpitaux de Rouen60
Enrolling By Invitation
Not Applicable
Influence of General Anesthesia on the Dynamic Changes in Brain Damage Markers During and After Craniosynostosis Operations in InfancyCraniosynostosisAnesthesia
NCT05911139Comenius University45
Completed
Not Applicable
Cerebral and Renal Oxymetry and Anesthetic Techniques in NewbornsCesarean Delivery Affecting Newborn
NCT03389139Antalya Training and Research Hospital60
Recruiting
Not Applicable
Neurodevelopment of Infants Exposed to General Anesthesia: a Multi-center InvestigationGeneral Anesthetics ToxicityNeurodevelopmentInfant
NCT03629093Huashan Hospital1,000
Completed
Phase 2
Effect of TAP Block on Time Required for First Analgesic Dose After Cesarean Cection Under Spinal AnesthesiaPostoperative Pain
NCT04623632Ain Shams Maternity Hospital60